Yabao Pharmaceutical Co, Inc., a leading pharmaceutical company in China, and LFB Biomedicaments, a fully-owned subsidiary of LFB SA, a French state-owned company, announced a strategic partnership to deliver LFB’s leading human albumin product Vialebex to China, which is the world’s largest human albumin market with annual growth of 29% from 2010 to 2014.

Under the terms of the agreement, Yabao receives exclusive rights to register Vialebex at the China Food and Drug Administration (CFDA) and further commercialize Vialebex in China. LFB shall exclusively supply Vialebex to Yabao using their specific expertise in bioproduction and biosafety. Financial terms were not disclosed.

"LFB’s Vialebex is a human albumin already registered and marketed in Europe and worldwide. Yabao is honoured to be collaborating with a long-established, global leader in human albumin and plasma-derived medicinal products," commented Dr. Peng Wang, president of R&D and head of international business, Yabao Pharmaceutical Co., "This ground-breaking commercial partnership with LFB is an important sign of Yabao's growing commitment to bringing world-class products such as Vialebex to China. Yabao is pleased to serve the growing need for high-quality human albumin to treat patients suffering from serious diseases in China."

Dr Philippe Gredy, MD, MSc, executive VP marketing and sales, stated, "We consider Yabao as a very valuable partner and are very pleased to have been chosen for our biopharmaceutical expertise. China is part of our strategy to grow internationally and we will do our best to serve the Chinese patients with high-quality medicinal products."

Vialebex is used for restoration and maintenance of circulating blood volume in cases of demonstrated hypovolemia when use of a colloid is appropriate.

The choice to use albumin rather than an artificial colloid should be made based on the patient’s clinical condition and official recommendations.

Vialebex is manufactured through a rigorously-controlled process conforming to specifications of European Pharmacopoeia. Fractionation way and specific purification steps processed in Vialebex are designed to provide an albumin with preserved properties of native human albumin, associated with a biosafety which is recognized for more than 20 years.

Yabao Pharmaceutical Co. is a leading Chinese pharmaceutical company with fully-integrated development, manufacturing, and commercialization capabilities.

LFB is a biopharmaceutical group that develops, manufactures, and markets medicinal products indicated in the treatment of serious and often rare diseases in haemostasis, immunology, and intensive care.